You just read:

Phase III Study Shows Eisai's First-In-Class Treatment Fycompa® (Perampanel) Significantly Reduces Primary Generalised Tonic-Clonic (PGTC) Seizures

News provided by

Eisai Europe Limited

17 Jun, 2014, 03:00 BST